Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which vaccine schedule keeps children protected longest?

NCT ID NCT06825312

Prevention Sponsor: Liaoning Chengda Biotechnology CO., LTD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This trial tests different vaccination schedules for Japanese encephalitis in healthy children starting at 8 months old. Researchers compare how well each schedule triggers and maintains protective antibodies through age 6, including the effect of booster doses. The study also monitors safety after each vaccine dose. The goal is to find the best way to protect children from this serious brain infection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Japanese encephalitis vaccine (inactivated and live versions)
What this could lead to
If successful, this could identify the most effective vaccination schedule for long-lasting protection against Japanese encephalitis in children.
What could go wrong
This is a phase 4 trial, so the vaccines are already licensed. The main uncertainty is which schedule offers the best antibody persistence, and results may vary by region or population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

8 to 8 months

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy children aged 8 months who are permanent residents of the study area. * Legal guardians can understand the requirements and processes of the study, provide written informed consent, and comply with all procedures as required by the clinical research protocol. * Able to receive the full course of Japanese encephalitis vaccinations according to the immunization strategy in the research protocol, including receiving the primary immunization at 8 months of age and the booster immunizations at 24 months of age and 6 years of age. Exclusion Criteria: * Unable to finish the full course of primary and booster immunizations at the study area, and unable to fulfill the follow-up visits prescribed in the protocol. * Non-compliance with the vaccination strategy for each group, as stated in the protocol, regarding Japanese encephalitis vaccines with proper doses and varieties. * Allergic to any component of the study vaccine or having a history of allergic reactions to any vaccines. * Having a history of symptoms or signs of neurological diseases or other contraindications for Japanese encephalitis vaccine vaccination. * Having used immunosuppressants or blood products following birth. * Receiving other vaccines simultaneously while receiving the Japanese encephalitis vaccine of this project. * Any conditions that may interfere with the evaluation of the study, as deemed by the researcher.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Japanese encephalitis vaccine are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Japanese encephalitis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Japanese encephalitis vaccine

Contacts and locations

Locations

  • Dongyang Center for Disease Control and Prevention

    Jinhua, Zhejiang, China

  • Jiangshan Center For Disease Control and Prevention

    Quzhou, Zhejiang, China

  • Jiashan County Center for Disease Control and Prevention

    Jiaxing, Zhejiang, China

  • Pinghu Center For Disease Control and Prevention

    Jiaxing, Zhejiang, China

  • Yongkang Center for Disease Control and Prevention

    Jinhua, Zhejiang, China

  • Yuyao Center for Disease Control and Prevention

    Ningbo, Zhejiang, China